UCLPartners Proactive Care Framework:

Lipid Management including Familial Hypercholesterolaemia
COVID-19 has placed unprecedented pressure on our health system. This brings an added risk to people with long term conditions who need ongoing proactive care to stay well and avoid deterioration. Disruption to routine care may worsen outcomes for patients, increase their COVID risk and result in exacerbations that further increase pressure on the NHS – driving demand for unscheduled care in GP practices and hospitals.

As primary care transforms its models of care in response to the pandemic, UCLPartners has developed real world frameworks to support proactive care in long term conditions. The frameworks include pathways for remote care, support for virtual consultations and more personalised care, and optimal use of the wider primary care team, e.g., healthcare assistants (HCA), link workers and pharmacists.

Additionally, the frameworks include a selection of appraised digital tools, training and other resources to support patient activation and self-management in the home setting.

This work has been led by primary care clinicians and informed by patient and public feedback.

The UCLPartners frameworks and support package will help Primary Care Networks and practices to prioritise in this challenging time and to focus resources on optimising care in patients at highest risk. It will support use of the wider workforce to deliver high quality proactive care and improved support for personalised care. And it will help release GP time in this period of unprecedented demand.
UCLPartners has developed a series of frameworks for local adaptation to support proactive management of long-term conditions in post-COVID primary care.

- Led by clinical team of GPs and pharmacists.
- Supported by patient and public insight.
- Working with local clinicians and training hubs to adapt and deliver.

Core principles:

1. Virtual where appropriate and face to face when needed.

2. Mobilising and supporting the wider workforce (including pharmacists, HCAs, other clinical and non-clinical staff).

3. Step change in support for self-management.

4. Digital innovation including apps for self-management and technology for remote monitoring.
CVD High Risk Conditions – Stratification and Management Overview

**Healthcare Assistants/other trained staff**

**Gather information e.g.** Up to date bloods, BP, weight, smoking status, run risk scores: QRISK, ChadsVasc, HASBLED.

**Self management e.g.** Education (condition specific, CVD risk reduction), self care (e.g., red flags, BP measurement, foot checks), signpost shared decision making.

**Behaviour change e.g.** Brief interventions and signposting e.g., smoking, weight, diet, exercise, alcohol.

---

**Risk Stratification & Prioritisation**

- **Atrial Fibrillation**
- **Blood Pressure**
- **Cholesterol**
- **Diabetes**

---

**Prescribing Clinician**

**Optimise therapy and mitigate risk**

- Review blood results, risk scores & symptoms.
- Initiate or optimise therapy.
- Check adherence and adverse effects.
- Review complications and co-morbidities.
- CVD risk – BP, cholesterol, pre-diabetes, smoking, obesity.
Why focus on Lipids

1. High cholesterol causes cardiovascular disease and accounts for a third of all heart attacks.

2. Lifestyle change is key to cholesterol lowering. Where this is ineffective or in people at highest risk (e.g. pre-existing CVD or familial hypercholesterolaemia (FH)), drug therapy with statins and other medications is very effective.

3. Every 1mmol/l reduction in low-density lipoproteins (LDL) cholesterol reduces risk of a cardiovascular event by 25% \(^1\).

4. People with high cholesterol who also have other risk factors (e.g. high blood pressure, diabetes, smoking) are at significantly greater risk of CVD and have most to gain from a reduction in cholesterol.

5. FH is high risk but very treatable. Half of men with FH will have a heart attack or stroke before age 50 and a third of women before age 60. Statins are highly effective at reducing this risk.

The following 4 slides offer a phased approach to lipid management guided by clinical priority, together with a pathway for FH case finding and management.
Cholesterol – Secondary Prevention (pre-existing CVD)

**Stratification**

**Healthcare assistants/other appropriately trained staff**

- Gather information *e.g.* up to date bloods, BP, weight, smoking status.
- Self-management *e.g.* Education (cholesterol, CVD risk), BP monitors (what to buy, how to use), signpost to shared decision making resources.
- Behaviour change *e.g.* Brief interventions and signposting *e.g.* smoking, weight, diet, exercise, alcohol.

**Prescribing clinician**

- **Priority One**
  - Not on statin therapy
- **Priority Two (A)**
  - On suboptimal intensity statin*
- **Priority Two (B)**
  - On suboptimal statin dose**
- **Priority Three – routine follow up**
  - Sub-optimal non-HDL (>2.5mmol/l) levels despite maximal statin therapy

**Optimise lipid modification therapy and CVD risk reduction**

1. Review CVD risk factors, lipid results and liver function tests.
2. Initiate or optimise statin to high intensity – *e.g.* atorvastatin 80mg.
3. Titrate therapy against reduction in LDLc/non-HDLc (statin>ezetimibe>PCSK9i).
4. Optimise BP and other comorbidities.
5. Use intolerance pathway and shared decision-making tools to support adherence.
6. Arrange follow-up bloods and review if needed.

---

* E.g simvastatin
** E.g atorvastatin 40mg
Cholesterol – Primary Prevention (no pre-existing CVD)

**Gather information:** E.g. up to date bloods, BP, weight, smoking status, run QRISK score.*

**Self-management:** Education (cholesterol, CVD risk), BP monitors (what to buy, how to use), signpost to shared decision making resources.

**Behaviour change:** Brief interventions and signposting e.g. smoking, weight, diet, exercise, alcohol.

**Optimise lipid modification therapy and CVD risk reduction**
1. Review QRISK score, lipid results and LFTs.
2. Initiate or optimise statin to high intensity – e.g. atorvastatin 20mg.
3. Titrate therapy against reduction in LDLc/non-HDLc (statin>ezetimibe).
4. Optimise BP and other comorbidities.
5. Use intolerance pathway and shared decision-making tools to support adherence.
6. Arrange follow-up bloods and review if needed.

*QRISK 3 score is recommended to assess CV risk for patients with Severe Mental Illness, Rheumatoid Arthritis, Systemic Lupus Erythematosus, those taking antipsychotics or oral steroids.
Familial Hypercholesterolaemia – Increasing Detection and Optimising Management

The UCLPartners FH pathway will help improve identification and management of patients with possible undiagnosed Familial Hypercholesterolaemia (FH).

Currently 92% of people with the condition are estimated to be undiagnosed. This pathway automates and simplifies this process and offers a pragmatic solution to case-finding.

The Simon Broome (SB) criteria can be used to determine if a patient with high cholesterol needs genetic testing.

1. Searches identify patients with a high cholesterol above the NICE recommended (CG71) thresholds.
2. An HCA or other team member then arranges fasting lipids plus renal, liver, thyroid and HbA1c to identify possible secondary causes of raised lipids. Cholesterol levels should then be re-checked after secondary causes are managed.
3. If the triglycerides are below 2.3mmol/l, a simplified family history questionnaire can be texted to the patient, with interpretation checked by the HCA. If family history of early CHD is positive, the Simon Broome criteria for genetic testing are met.
4. If family history is negative, the patient should be assessed for tendon xanthomata (TX). This service could be provided across a PCN or CCG by a trained pharmacist or nurse. If TX are present, the Simon Broome criteria for genetic testing are met.
5. For patients in whom Simon Broom criteria are met and for those with known (coded) FH, a desktop review is conducted by a trained pharmacist or nurse to check results and coding, exclude secondary causes for the elevated lipid levels and referral to specialist service for assessment and genetic testing.
Implementation Resources

1. Optimisation Pathway for Secondary Prevention
2. Optimisation Pathway for Primary Prevention
3. Statin Intolerance Pathway
4. Muscle Symptoms Pathway
5. Abnormal Liver Function Test Pathway
6. Shared Decision-Making Resources
7. QRISK3
8. Desktop Review and Overview of Medicines Optimisation in FH
9. FH questionnaire
Optimisation Pathway for Secondary Prevention

Is patient on high dose, high intensity statin*?
(atorvastatin 80mg or equivalent)

Yes

Increase to high dose high intensity statin *** and re-enforce lifestyle and diet measures

Non-HDL-C reduced by 40% or more from baseline at 3 months? ****
(if baseline non-HDL not available, consider intensification of therapy if non-HDL-C > 2.5mmol/L)

Yes

Check adherence to statin and lifestyle measures **

Consider adding ezetimibe 10mg daily

After 3 months, check fasting lipids. If LDL cholesterol > 4mmol/L (or 3.5 if recurrent CV events), refer for consideration of PCSK9i

Specialist service review and intervention

Review annually for adherence to drugs and support for diet and lifestyle measures

No

No

Optimal High Intensity Statin for secondary prevention
(High intensity statins are substantially more effective at preventing cardiovascular events than low/medium intensity statins)

Atorvastatin 80mg

Rosuvastatin 20mg

* Dose may be limited if:
  - eGFR<30ml/min
  - Drug interactions
  - Intolerance

** If statin not tolerated, follow statin intolerance pathway and consider ezetimibe 10mg daily +/- bempedoic acid 180mg daily

*** See statin intensity table

**** NICE Guidance recommends a 40% reduction in non-HDL cholesterol
**Optimisation Pathway for Primary Prevention**

1. **Is patient on high intensity statin?**
   - **Yes**: Begin atorvastatin 20mg/day
   - **No**: After 3 months - has non-HDL-C reduced by 40% or more from baseline?
     - **Yes**: Check adherence and tolerance*
       - Titrate statin up to maximum atorvastatin 80mg or equivalent
       - If non-HDL cholesterol has not fallen by 40% or more from baseline, consider adding ezetimibe 10mg daily
     - **No**: Review annually for adherence to drugs, diet and lifestyle

2. **Optimal High Intensity statin for Primary Prevention**
   (High intensity statins are substantially more effective at preventing cardiovascular events than low/medium intensity statins)

   - Atorvastatin 20mg
   - Rosuvastatin 10mg

   *If statin not tolerated, follow statin intolerance pathway and consider ezetimibe 10mg daily +/− bempedoic acid 180mg daily
Statin Intolerance Pathway

**Important considerations**

- Most adverse events attributed to statins are no more common than placebo*.
- Stopping statin therapy is associated with an increased risk of major CV events. It is important not to label patients as ‘statin intolerant’ without structured assessment.
- If a person is not able to tolerate a high-intensity statin, aim to treat with the maximum tolerated dose.
- A statin at any dose reduces CVD risk – consider annual review for patients not taking statins to review cardiovascular risk and interventions.

---

**A structured approach to reported adverse effects of statins**

1. Stop for 4-6 weeks.
2. If symptoms persist, they are unlikely to be due to statin.
3. Restart and consider lower initial dose.
4. If symptoms recur, consider trial with alternative statin.
5. If symptoms persist, consider ezetimibe +/- bempedoic acid.

*(Collins et al. systematic review, Lancet 2016)*
**Muscle Symptoms Pathway**

**Muscle Symptoms**
- **Check CK**

**CK >50x ULN**
- Consider rhabdomyolysis. Stop statin and seek specialist advice urgently
- Seek specialist advice if CK not normalised

**CK >10-50 ULN**
- Check renal function
  - **Yes**
    - Renal function deteriorating?
      - **Yes**
        - Discuss with patient. Continue statin and review at 2 weeks. Consider lower dose or alternative statin
      - **No**
        - Stop statin for 4-6 weeks. 2 weeks after symptoms resolved and CK normalised, restart statin at lower dose (Or consider low dose rosuvastatin if on atorvastatin and titrate up)
  - **No**
    - **Tolerable symptoms**
    - **No improvement in CK or symptoms intolerable**
      - Consider rhabdomyolysis. Stop statin and seek specialist advice urgently

**CK >4-10 ULN**
- **Check renal function**
- **No**

**CK 0-4x ULN**
- **No improvement in CK or symptoms intolerable**
- **Tolerable symptoms**
  - Discuss with patient. Continue statin and review at 2 weeks. Consider lower dose or alternative statin

**Detailed guidance:**

**If recurrence of symptoms - Consider ezetimibe +/- bempedoic acid and/or referral for PCSK9i (for secondary prevention)**

**Monitor CK, continue statin and review at 6 weeks**
Abnormal Liver Function Test Pathway

Abnormal LFTs

If transaminase is raised >3 times

Stop statin and restart once LFTs normalise

If transaminase is raised <3 times

Continue and repeat 1 months – if <3x ULN – continue and repeat at 6 months

Consider other causes of abnormal LFT – alcohol, fatty liver, cirrhosis, cancer, hepatitis etc and investigate/treat appropriately.

Seek specialist advice if concern of causal relationship between statin and of liver damage.

- Do not routinely exclude from statin therapy people who have liver transaminase levels that are raised but are less than 3 times the upper limit of normal.
- Most adults with fatty livers are likely to benefit from statins and this is not a contraindication.
- Check liver function at baseline, and once between 3 months and 12 months after initiation of statin therapy.
### Benefits per 10,000 people taking statin for 5 years

<table>
<thead>
<tr>
<th>Event Description</th>
<th>Events avoided</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avoidance of major CVD events in patients with pre-existing CVD &amp; a 2mmol/l reduction in LDL</td>
<td>1,000</td>
</tr>
<tr>
<td>Avoidance of major CVD events in patients with no pre-existing CVD &amp; a 2mmol/l reduction in LDL</td>
<td>500</td>
</tr>
</tbody>
</table>

### Adverse events per 10,000 people taking statin for 5 years

<table>
<thead>
<tr>
<th>Event Description</th>
<th>Adverse events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myopathy</td>
<td>5</td>
</tr>
<tr>
<td>Haemorrhagic Strokes</td>
<td>5-10</td>
</tr>
<tr>
<td>Diabetes Cases</td>
<td>50-100</td>
</tr>
</tbody>
</table>

### Shared decision-making resources:

- [BHF information on statins](#)
- [Heart UK: Information on statins](#)
- [NICE shared decision-making guide](#)
# Statin Intensity Table – NICE recommends Atorvastatin and Rosuvastatin as First Line

<table>
<thead>
<tr>
<th>Statin dose mg/day</th>
<th>5</th>
<th>10</th>
<th>20</th>
<th>40</th>
<th>80</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluvastatin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pravastatin</td>
<td>20%</td>
<td>24%</td>
<td>29%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Simvastatin</td>
<td>27%</td>
<td>32%</td>
<td>37%</td>
<td>42%</td>
<td></td>
</tr>
<tr>
<td>Atorvastatin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>43%</td>
</tr>
<tr>
<td>Rosuvastatin</td>
<td>38%</td>
<td>43%</td>
<td>48%</td>
<td>53%</td>
<td></td>
</tr>
<tr>
<td>Atorvastatin + Ezetimibe 10mg</td>
<td></td>
<td></td>
<td>52%</td>
<td>54%</td>
<td>57%</td>
</tr>
</tbody>
</table>

- **Low/moderate intensity statins** will produce an LDL-C reduction of 20-30%
- **Medium intensity statins** will produce an LDL-C reduction of 31-40%
- **High intensity statins** will produce an LDL-C reduction above 40%
- **Simvastatin 80mg** is not recommended due to risk of muscle toxicity
QRISK® 3 includes more factors than QRISK® 2 to help identify those at most risk:

- Chronic kidney disease, which now includes stage 3 CKD
- Migraine
- Corticosteroids
- Systemic lupus erythematosus (SLE)
- Atypical antipsychotics
- Severe mental illness
- Erectile dysfunction
- A measure of systolic blood pressure variability
**Desktop Review for People with Coded FH**

1. Identify patients coded as Familial Hypercholesterolemia
2. Review notes and medications
3. Have they had a genetic test to confirm diagnosis?
   - Yes
     - Are they under regular lipid clinic review?
       - Yes: Continue management as per specialist team
       - No: Consider referral to lipid clinic if appropriate
   - No: Calculate probability of FH using Dutch lipid criteria and refer to specialist lipid clinic if meets criteria
Overview of Medicines Optimisation in FH

1. Offer a high-intensity statin to all adults with FH
2. Aim for at least a 50% reduction in LDL-C concentration
3. Increase the dose of statin after 3 months if not achieving a 50% reduction in LDL-C and not already prescribed maximum dose
4. Use ezetimibe in patients with FH who have contraindications to or cannot tolerate statin therapy and consider adding bempedoic acid
5. Add ezetimibe to statin therapy in patients who are not achieving a 50% reduction in LDL-C concentration despite maximum dose high intensity statin OR where statin dose is limited by side effects
6. Refer patients to a specialist:
   - if treatment with the maximum tolerated dose of a high-intensity statin and ezetimibe is inadequate
   - if they are assessed to be at very high risk of a coronary event:
     - Established coronary heart disease
     - A family history of premature coronary heart disease
     - Two or more other cardiovascular risk factors (for example, they are male, they smoke, or they have hypertension or diabetes)
7. Specialists may initiate PCSK9i (alirocumab or evolocumab), bile acid binders (resins) or fibrates in patients with an inadequate response to first line lipid lowering therapies.
8. PCSK9i are recommended for use in people with FH:
   - For primary prevention when LDL remains > 5mmol/L despite optimal statin / ezetimibe therapy
   - For secondary prevention when LDL remains > 3.5mmol/L despite optimal statin / ezetimibe therapy
We have reviewed your cholesterol results and would like some information on your family history to help inform your treatment. Please answer the following questions:

1. Have any of your first-degree blood relatives (mother, father, brother or sister) had a heart attack under the age of 60?  
   - Yes/ No
   - If Yes, which relative (mention how they are related to you) and how old were they when they had the heart attack?

2. Have any of your second-degree blood relatives (grandparents, aunts, uncles, nephews, nieces and half brothers and half sisters) had a heart attack aged 50 or under?  
   - Yes/ No
   - If Yes, which relative (mention how they are related to you) and how old were they when they had the heart attack?
# Dutch Lipid Clinic Criteria

## Family history
- First-degree relative with known premature coronary and/or vascular disease (men aged <55 years and women aged <60 years)
  - or
- First-degree relative with known low-density lipoprotein-cholesterol (LDL-C) above the 95th percentile for age and sex
- First-degree relative with tendinous xanthomata and/or arcus cornealis
- Children aged <18 years with LDL-C above the 95th percentile for age and sex

## Clinical history
- Patient with premature coronary artery disease (ages as above)
- Patient with premature cerebral or peripheral vascular disease (as above)

## Physical examination
- Tendon xanthomas
- Arcus cornealis prior to 45 years of age
- LDL-C (mmol/L)
  - LDL-C ≥8.5
  - LDL-C 6.5–8.4
  - LDL-C 5.0–6.4
  - LDL-C 4.0–4.9

Deoxyribonucleic acid (DNA) analysis: Functional mutation in the low-density lipoprotein receptor (LDLR), apolipoprotein B (APOB) or proprotein convertase subtilisin/kexin type 9 (PCSK9) gene

## Stratification
- Definite familial hypercholesterolaemia (FH)
- Probable FH
- Possible FH
- Unlikely FH

<table>
<thead>
<tr>
<th>Total score</th>
<th>Definite familial hypercholesterolaemia (FH)</th>
<th>Probable FH</th>
<th>Possible FH</th>
<th>Unlikely FH</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥8</td>
<td></td>
<td>6–7</td>
<td>3–5</td>
<td>&lt;3</td>
</tr>
</tbody>
</table>

*ApoB*, apolipoprotein B; DNA, deoxyribonucleic acid; FH, familial hypercholesterolaemia; LDL-C, low-density lipoprotein-cholesterol; LDLR, low-density lipoprotein receptor; PCSK9, proprotein convertase subtilisin/kexin type 9
Hypertension in patients with Hypercholesterolaemia
Detection and Management of Hypertension in Patients with Hypercholesterolaemia

Blood pressure should be checked in patients with hypercholesterolaemia to identify undiagnosed hypertension. If hypertension is suspected due to a high BP reading, the diagnosis should be confirmed using ABPM or home BP checks over 7 days.

Checking BP in patients with established hypertension:

• Patients **without** AF:
  o Submit lowest of 3 Home BP readings

• Patients **with** AF:
  o Submit 2 BP readings each morning and evening over 4 days. Calculate the average systolic and diastolic values.

• Please refer to UCLP hypertension pathway for detailed guidance:
Home Blood Pressure Monitoring Pathway

**Patient has BP monitor** (confirm by text)

- **Phase over time**
  - Advise patient to check if approved monitor (Text link) and confirm < 5 years old

- **Phase over time**
  - Wellbeing staff to teach BP technique & pulse check technique (with video resources)

**Face to face BP options**
- Community pharmacy
- GP practice
- Other community settings

**Home BP readings** submitted using locally agreed tool

**Detection of AF**
- Remote (e.g., Fibricheck or mobile ECG device)
- Face to face pulse/ECG

**Confirmed AF diagnosis**
- Pulse irregular or patient uncertain

**Average of multiple BP readings** (see hypertension pack)

**Assess for anticoagulation and manage AF in line with local pathways**

**No AF**

**No BP monitor**

1. Advise patient to buy a BP monitor (see slide 5) or
2. Local scheme to supply BP monitor

**No BP monitor**
Choice of antihypertensive drug\(^1\), monitoring treatment and BP targets

### Monitoring treatment

Use clinic BP to monitor treatment.

- Measure standing and sitting BP in people with:
  - type 2 diabetes or
  - symptoms of postural hypotension or
  - aged 80 and over.

Advise people who want to self-monitor to use HBPM. Provide training and advice.

Consider ABPM or HBPM, in addition to clinic BP, for people with white-coat effect or masked hypertension.

### BP targets

Reduce and maintain BP to the following targets:

- **Age <80 years**:
  - Clinic BP <140/90 mmHg
  - ABPM/HBPM <135/85 mmHg

- **Age ≥80 years**:
  - Clinic BP <150/90 mmHg
  - ABPM/HBPM <145/85 mmHg

**Postural hypotension**:
- Base target on standing BP

**Frailty or multimorbidity**:
- Use clinical judgement

---

\(^1\) For women considering pregnancy or who are pregnant or breastfeeding, see NICE’s guideline on hypertension in pregnancy. For people with chronic kidney disease, see NICE’s guideline on chronic kidney disease. For people with heart failure, see NICE’s guideline on chronic heart failure.

\(^2\) See M-BRA drug safety updates on ACE inhibitors and angiotensin II receptor antagonists not for use in pregnancy, which states “Use in women who are planning pregnancy should be avoided unless absolutely necessary, in which case the potential risks and benefits should be discussed. ACE inhibitors and angiotensin II receptor antagonists have a UK marketing authorisation for this indication.”

\(^3\) Consider an ARB in preference to an ACE inhibitor in adults of African and Carribbean family origin.

\(^4\) All the time of publication (August 2019), not all preparations of spironolactone have a UK marketing authorisation for this indication.

Abbreviations: ABPM, ambulatory blood pressure monitoring; ACE, ACE inhibitor; ARB, angiotensin II receptor blocker; BP, blood pressure; CCB, calcium-channel blocker; HBPM, home blood pressure monitoring.
Atrial Fibrillation in Patients with Hypercholesterolaemia
Detection and Management of AF in Patients with Hypercholesterolaemia

• Palpate pulse and if irregular or patient uncertain:
  o Assess for AF using ECG or remote devices:
    ▪ Fibricheck (needs smartphone) www.fibricheck.com/ and ask them to monitor morning and evening for 7 days
    ▪ Kardia by AliveCor (needs smartphone): www.alivecor.co.uk/kardiamobile
    ▪ MyDiagnostick: www.mydiagnostick.com/
    ▪ Zenicor: https://zenicor.com/

• If AF is confirmed, undertake stroke and bleeding risk assessment and anticoagulate as appropriate.

• Please refer to UCLP AF pathway for detailed guidance: https://s31836.pcdn.co/wp-content/uploads/Atrial-Fibrillation-Framework_UCLPartners-LTCs-April-2021-v2.0.pdf
Digital Resources
Digital Resources to Support Self-Management: Cholesterol

• Heart UK resources
  Healthy Eating, blood fats explained, understanding cholesterol, and Familial Hypercholesterolemia

• British Heart Foundation resources - Understanding Cholesterol

• Diet
  Providing information and recipes for easy ways to eat better from the ‘One You’ website
  NHS advice on lowering cholesterol levels

• Smoking cessation
  NHS support, stop smoking aids, tools and practical tips

• Exercise
  NHS ‘One You’
  iPrescribe app offers a tailored exercise plan by creating a 12-week exercise plan based on health information entered by the user
  Getting active around the home: tips, advice and guidance on how to keep or get active in and around the home from Sport England
  Dance to health: Online dance programme especially tailored to people over 55 years old

• Alcohol
  Heart UK alcohol guidance
  NHS Drink Less guidance

• Mental Health - Tips and suggestions for looking after your mental health

• Peer support - Communities of people living with high cholesterol
Proactive Care Frameworks: Implementation & Support Package

Implementation Support is critical to enable sustainable and consistent spread. UCLPartners has developed a support package covering the following components:

**Search and stratify**
- **Comprehensive search tools** for EMIS and SystmOne to stratify patients
  - Pre-recorded webinar as to how to use the searches
  - Online Q&A to troubleshoot challenges with delivery of the search tools

**Workforce training and support**
- **Training tailored to each staff grouping (e.g. HCA/ pharmacist etc) and level of experience**
  - **Delivery:** Protocols and scripts provided/ training on how to use these underpinned with motivational interviewing/ health coaching training to enable adult-to-adult conversations
  - **Practical support:** e.g. correct inhaler technique; correct BP technique, Very Brief Advice for smoking cessation, physical activity etc
  - **Digital implementation** support: how to get patients set up with appropriate digital
  - **Education** sessions on conditions
  - **Communities of Practice**

**Digital support tools**
- **Digital resources** to support remote management and self-management in each condition
- **Implementation** toolkits available where required, e.g. MyCOPD
- Support available from UCLP’s commercial and innovation team for implementation
References


2. NHS England statin intolerance pathway

3. NHS England summary of lipid management national guidance

4. NICE cardiovascular disease clinical guidance

5. NICE secondary prevention clinical guidance

6. European Heart Journal, Volume 37, Issue 29, 1 August 2016, Pages 2315–2381

Thank you

For more information please contact:
primarycare@uclpartners.com

www.uclpartners.com
@uclpartners
## Version tracker

<table>
<thead>
<tr>
<th>Version</th>
<th>Edition</th>
<th>Changes Made</th>
<th>Date amended</th>
<th>Review date</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>2.0</td>
<td>• Edited the stratification overview slide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>3.0</td>
<td>• FH pathway updated and guidance for detection</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Addition of Medicines Optimisation approach</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Guidance on desk top reviews and use of Dutch Lipid Clinic criteria</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>4.0</td>
<td>• Formatting and slide order</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>4.1</td>
<td>• Formatting</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>5.0</td>
<td>• Hypertension slides added. Dates added to version control table and version number removed from title slide</td>
<td>June 2021</td>
<td>December 2021</td>
</tr>
<tr>
<td>6</td>
<td>6.0</td>
<td>• Slide order re-arranged</td>
<td>August 2021</td>
<td>February 2022</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Detection and management of AF added</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Added option of bempedoic acid</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>